戻る Agenda
Session 7: Adapting Health Product Advertising Oversight to the Digital Environment and Closing Remarks
Session Chair(s)
Kristin Willemsen, MS
Vice President, Scientific & Regulatory Affairs
Food, Health & Consumer Products of Canada, Canada
Misinformation is becoming a threat to public health and the healthcare system, particularly given the prevalence of inaccurate health information online. Given Canadians and healthcare practitioners are increasingly seeking out digital information about health products to inform choices, how can Health Canada keep up and enforce against misleading health product information online? In this session, you will hear from the Marketed Health Products Directorate about how they modernized policies and regulatory oversight, and tools and processes to adapt to the digital environment. These initiatives are intended to increase compliance and enforcement of the Food and Drugs Act, the Controlled Drugs and Substances Act and their associated regulations. Opportunities to further improve oversight will also be discussed.
Learning Objective : - Apply the revised policy that distinguishes between promotional and non-promotional messages to digital forms of communication
- Identify how Health Canada harnessed artificial intelligence to increase surveillance and enforce against misleading COVID claims, and how this new process is being piloted to address misleading NHP advertising
- Anticipate future measures to improve oversight of health product advertising and promotions
Speaker(s)
Overview of Distinction Policy
Alain G. Musende, PhD
Marketed Health Products Directorate, Health Canada, Canada
Manager, Section for Transparency and Advertising Regulatory Surveillance
Taking Action on Misleading COVID-19 Related Claims
Rim Lejmi Mrad, PhD
Health Canada, Canada
Supervisor, Marketed Health Products Decorate